Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.12|
|52 Week High||AU$1.06|
|52 Week Low||AU$1.71|
|1 Month Change||-16.42%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-25.33%|
Recent News & Updates
|CU6||AU Pharmaceuticals||AU Market|
Return vs Industry: Insufficient data to determine how CU6 performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CU6 performed against the Australian Market.
Stable Share Price: CU6 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: Insufficient data to determine CU6's volatility change over the past year.
About the Company
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.
Clarity Pharmaceuticals Fundamentals Summary
|CU6 fundamental statistics|
Is CU6 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CU6 income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.04|
|Net Profit Margin||-319.77%|
How did CU6 perform over the long term?See historical performance and comparison
Is Clarity Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CU6 (A$1.12) is trading below our estimate of fair value (A$33.33)
Significantly Below Fair Value: CU6 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CU6 is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: CU6 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CU6's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CU6 is overvalued based on its PB Ratio (14.1x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Clarity Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CU6 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: CU6 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CU6's is expected to become profitable in the next 3 years.
Revenue vs Market: CU6's revenue (50.4% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: CU6's revenue (50.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CU6's Return on Equity is forecast to be low in 3 years time (6%).
How has Clarity Pharmaceuticals performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CU6 is currently unprofitable.
Growing Profit Margin: CU6 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CU6's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CU6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CU6 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: CU6 has a negative Return on Equity (-50.41%), as it is currently unprofitable.
How is Clarity Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CU6's short term assets (A$22.5M) exceed its short term liabilities (A$2.3M).
Long Term Liabilities: CU6's short term assets (A$22.5M) exceed its long term liabilities (A$84.7K).
Debt to Equity History and Analysis
Debt Level: CU6 is debt free.
Reducing Debt: CU6 has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CU6 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CU6 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 36.7% each year.
What is Clarity Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CU6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CU6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CU6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CU6's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CU6's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Colin David Biggin, Ph D., has been Managing Director, Chief Executive Officer and Executive Director at Clarity Pharmaceuticals Ltd since October 1, 2019. Dr. Biggin joined Clarity Pharmaceuticals Pty...
CEO Compensation Analysis
Compensation vs Market: Colin's total compensation ($USD668.46K) is about average for companies of similar size in the Australian market ($USD563.48K).
Compensation vs Earnings: Colin's compensation has increased whilst the company is unprofitable.
Experienced Board: CU6's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: CU6 only recently listed within the past 12 months.
Clarity Pharmaceuticals Ltd's employee growth, exchange listings and data sources
- Name: Clarity Pharmaceuticals Ltd
- Ticker: CU6
- Exchange: ASX
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$275.342m
- Shares outstanding: 256.13m
- Website: https://www.claritypharmaceuticals.com
- Clarity Pharmaceuticals Ltd
- National Innovation Centre
- 4 Cornwallis Street
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/14 07:02|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.